UNIGE document Scientific Article
previous document  unige:99116  next document
add to browser collection

A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa

Haks, Mariëlle C
Quinten, Edwin
Agnandji, Selidji Todagbe
Brosnahan, Jessica
show hidden authors show all authors [1 - 17]
Published in Science Translational Medicine. 2017, vol. 9, no. 385
Abstract The 2014-2015 Ebola epidemic affected several African countries, claiming more than 11,000 lives and leaving thousands with ongoing sequelae. Safe and effective vaccines could prevent or limit future outbreaks. The recombinant vesicular stomatitis virus-vectored Zaire Ebola (rVSV-ZEBOV) vaccine has shown marked immunogenicity and efficacy in humans but is reactogenic at higher doses. To understand its effects, we examined plasma samples from 115 healthy volunteers from Geneva who received low-dose (LD) or high-dose (HD) vaccine or placebo. Fifteen plasma chemokines/cytokines were assessed at baseline and on days 1, 2 to 3, and 7 after injection. Significant increases in monocyte-mediated MCP-1/CCL2, MIP-1β/CCL4, IL-6, TNF-α, IL-1Ra, and IL-10 occurred on day 1. A signature explaining 68% of cytokine/chemokine vaccine-response variability was identified. Its score was higher in HD versus LD vaccinees and was associated positively with vaccine viremia and negatively with cytopenia. It was higher in vaccinees with injection-site pain, fever, myalgia, chills, and headache; higher scores reflected increasing severity. In contrast, HD vaccinees who subsequently developed arthritis had lower day 1 scores than other HD vaccinees. Vaccine dose did not influence the signature despite its influence on specific outcomes. The Geneva-derived signature associated strongly (ρ = 0.97) with that of a cohort of 75 vaccinees from a parallel trial in Lambaréné, Gabon. Its score in Geneva HD vaccinees with subsequent arthritis was significantly lower than that in Lambaréné HD vaccinees, none of whom experienced arthritis. This signature, which reveals monocytes' critical role in rVSV-ZEBOV immunogenicity and safety across doses and continents, should prove useful in assessments of other vaccines.
Keywords AfricaEbola Vaccines/adverse effects/immunologyEuropeFemaleHemorrhagic Fever, Ebola/blood/immunologyHumansMacrophages/metabolismMale
PMID: 28404856
Full text
Article (Published version) (1.1 MB) - document accessible for UNIGE members only Limited access to UNIGE
Research groups Centre de vaccinologie et d'immunologie néonatale (177)
Epidémiologie clinique (115)
Etude de l'activation des monocytes/macrophages et des polynucléaires neutrophiles (779)
Groupe Laurent Kaiser (virologie clinique) (668)
(ISO format)
CSAKI HUTTNER, Angela et al. A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa. In: Science Translational Medicine, 2017, vol. 9, n° 385. doi: 10.1126/scitranslmed.aaj1701 https://archive-ouverte.unige.ch/unige:99116

406 hits



Deposited on : 2017-11-16

Export document
Format :
Citation style :